Transcranial photobiomodulation in therapy of neurodegenerative diseases of the brain: theoretical background and clinical effectiveness

Белова, А. Н.; Israelyan, Yu.A.; Сушин, В О; Shabanova, M.A.; Rezenova, A.M.

doi:10.17116/kurort20219806161

Cited by 5 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…73 Nine articles of clinical research including 8 articles of clinical studies 37,42,[74][75][76][77][78][79] and a clinical trial 43 were found. The rest of the articles include 21 review articles 22,25,32,41,[80][81][82][83][84][85][86][87][88][89][90][91][92][93][94][95][96] and a systematic review 97 with focused content on PD, and 7 review articles 38,[98][99][100][101][102][103] with the term PD merely mentioned along with other neurodegenerative diseases such as Alzheimer's disease for general description of therapeutic application of PBM.…”

Section: Resultsmentioning

confidence: 99%

Progress of Photobiomodulation for Parkinson’s Disease

Tsai¹

2022

SOJCEM

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a neurodegenerative disease with global burden. The mechanisms and therapeutic effects of photobiomodulation (PBM) correspond to main mechanisms in the pathogenesis of PD. Numerous research results applying PBM for PD were published during the past two decades. Although several systematic review or review articles provided complete introduction, they are either mainly basic research or clinical research, and the year of the article publication is up to 2020. Comprehensive systematic review or review articles containing basic and clinical studies including those published articles is lacking. Hence, this systematic review aimed to include both basic and clinical studies published up to 2022. Results were obtained by retrieving articles from PubMed with the intersection of the articles derived from the terms of PBM synonyms and Parkinson’s disease followed by exclusion. Sixty-nine articles were included ultimately. Among them, 40 original articles were identified, which were composed of 31 basic research and 9 original articles of clinical research. Twenty-one review articles, a systematic review with focused content on PD, and 7 review articles with the term PD under general illustration of PBM were presented. Mechanisms regarding the therapeutic effects of PBM on the vitro studies were reviewed. Positive outcomes on motor symptoms after PBM treatments were shown in most in vivo and clinical studies. The immunohistochemical examination of in vivo studies reflect the therapeutic effects of PBM on the preservation even reverse of the pathogenic insults of PD on the in vitro studies. The most frequently used wavelength among original articles included was 670nm. Considering the acceptability of PBM for patients with PD, noninvasive transcranial PBM (tPBM) had crucial roles in respect to invasive intracerebral PBM. To match the penetration depth reaching deep brain target, Substantia nigra pars compacta, in human brains of patients with PD, the wavelength 810nm might match the need in the clinical setting of tPBM. More future clinical studies were needed. In conclusion, therapeutic approaches applying PBM for PD are promising. Recent studies revealed positive outcomes. Future clinical practices containing PBM are to be expected.

show abstract

Section: Resultsmentioning

confidence: 99%

Progress of Photobiomodulation for Parkinson’s Disease

Tsai¹

2022

SOJCEM

View full text Add to dashboard Cite

show abstract

“…The interrelationship between the gut's microbiome, the brain, and Parkinson's disease (PD), as well as the type of clinical expression of SARS-CoV-2 infection on the gut-lung-brain axis, is already known. PBMT applied in animal models improved PD symptoms [83] and protected neurons from degradation when used directly on the cephalic extremity [84,85], or on other areas of the body (e.g., the abdomen). Liebert et al aimed to evaluate whether the application of remote PBMT has an influence on the reduction of clinical manifestations of PD.…”

Section: Discussionmentioning

confidence: 99%

Light as a Cure in COVID-19: A Challenge for Medicine

Ailioaie

Ailioaie²,

Litscher³

2022

Photonics

View full text Add to dashboard Cite

Light and lasers, as high-tech devices whose medical potential has yet to be fully discovered, have made important contributions to medicine, even in the current pandemic. The main aim of this review was to investigate how light was applied as a therapeutic tool during a crisis triggered by COVID-19. Another goal was to encourage scientists and industry to quickly design new at-home photobiomodulation therapy (PBMT) and/or antimicrobial photodynamic therapy (aPDT) easy to use systems to end this pandemic, especially for those who believe in high-tech but would never get vaccinated. This review revealed that PBMT has been successfully applied as adjunct therapy, in combination with conventional medical treatment, and as a pioneering action in SARS-CoV-2 infection, demonstrating significant improvements in airway inflammation and general clinical condition of patients, a faster recovery, avoiding intensive care unit (ICU) hospitalization, mechanical ventilation, mortality, and overcoming long-term sequelae. Application in only a limited number of cases strongly suggests the need for future randomized, placebo-controlled clinical trials to objectively determine the action and effects of PBMT in COVID-19. Implementation of unparalleled theragnostics methods and light-based techniques for disinfection of spaces, air, skin, mucosae, and textures to decrease the load of SARS-CoV-2 virus would save lives, time, and money. In this ongoing and challenging search for the seemingly intangible end of this pandemic, a non-invasive, easily accessible, safe, and side-effect-free adjuvant method appears to be PBMT, alone or in synergistic combination with aPDT, which has been shown to work in COVID-19 and opens unprecedented potential for use as home self-treatment to end the pandemic.

show abstract

“…To this day, some publications identify it with PBM, despite the fundamentally large breadth of this concept. Among the light sources, the most commonly used for photobiomodulation are those that produce light with a wavelength corresponding to the red and near infrared regions (600-1100 nm) [1,6,11,13,15,26].…”

Section: Introductionmentioning

confidence: 99%

“…On this basis, transcranial photobiomodulation is the most optimal and universal option. Transcranial photobiomodulation is a form of light therapy using monochromatic light in the visible and infrared ranges from non-ionizing radiation sources (lasers, LEDs), which are placed on the scalp, on the forehead or intranasally in such a way as to project a luminous flux directly onto the target areas of the brain [1,6,39,47]. In recent years, there has been an avalanche-like increase in the interest of neurologists and psychiatrists in transcranial photobiomodulation, however, a systematization of empirical data and the fundamental foundations of technology is required.…”

Section: Introductionmentioning

confidence: 99%

Transcranial Photobiomodulation in Neurological and Psychiatric Practice: Fundamental and Clinical Aspects

Martusevich,

Bogachek,

Nazarov

2024

ArveMED

View full text Add to dashboard Cite

Photobiomodulation is a relatively young medical technology that integrates the efforts of physicists, engineers and specialists in the field of biomedicine and includes various methods of light exposure to cells and tissues of the body. The main options for such effects are light radiation of the visible and IR spectrum generated by LED sources, and low-intensity laser radiation (LILI), which requires the use of lasers with special characteristics. In recent years, there has been an avalanche of interest among neurologists and psychiatrists in transcranial photobiomodulation, However, a systematization of empirical data and the fundamental foundations of technology is required. On this basis, the purpose of the review is to integrate ideas about the molecular-cellular and systemic effects of transcranial photobiomodulation and the prospects for its application in neurological and psychiatric practice. We have shown that intensive research in the field of studying the biological effects of low–intensity laser radiation, red and infrared light, which made it possible to decipher the main ways of responding to it at the molecular, cellular and tissue levels, created prerequisites for the formation of a new synthetic scientific direction - photobiomics. This translational discipline is focused on the development of pathogenetically sound technologies for the treatment of diseases of various profiles, including neurological and mental pathology. The results of experimental and clinical studies presented in the literature indicate the effectiveness of photobiomodulation in depression and post-traumatic stress disorder, nevertheless, extensive trials and meta-analyses are advisable for their full inclusion in international clinical recommendations.

show abstract

Transcranial photobiomodulation in therapy of neurodegenerative diseases of the brain: theoretical background and clinical effectiveness

Cited by 5 publications

References 43 publications

Progress of Photobiomodulation for Parkinson’s Disease

Progress of Photobiomodulation for Parkinson’s Disease

Light as a Cure in COVID-19: A Challenge for Medicine

Transcranial Photobiomodulation in Neurological and Psychiatric Practice: Fundamental and Clinical Aspects

Contact Info

Product

Resources

About